Intraparenchymal haematoma of the central nervous system associated with Dasatinib in the treatment of chronic myeloid leukaemia in accelerated phase. Presentation of two cases and review of literature
Keywords:
Chronic myeloid leukaemia, Dasatinib, Intracerebral haemorrhage, Adverse effectAbstract
Two clinical cases are presented on patients with chronic myeloid leukaemia in accelerated phase, who were admitted to hospital for initiation of targeted therapy with tyrosine kinase inhibitors (Dasatinib). Intraparenchymal bleeding in the central nervous system was subsequently
observed. A review was also made on the available literature on bleeding-related adverse events associated with Dasatinib and the possible determining factors of this outcome.
Author Biographies
Leonardo Bautista Toloza, Universidad Nacional de Colombia
Grupo de Investigación en Hematología Clínica, Universidad Nacional de Colombia, Bogotá D.C., Colombia
Humberto Martínez, Instituto Nacional de Cancerología
Servicio de Hematología, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
Orlando Bonell Patiño, Instituto Nacional de Cancerología
Servicio de Hematología, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
References
Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385:1447-59.
https://doi.org/10.1016/S0140-6736(13)62120-0
Goldman J, Melo J. Chronic myeloid leukemia - Advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-64.
https://doi.org/10.1056/NEJMra020777
Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-405.
https://doi.org/10.1182/blood-2016-03-643544
Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood. 2012;120:1390-7.
https://doi.org/10.1182/blood-2012-03-378919
Ault P. Dasatinib in the first-line treatment of chronic myeloid leukemia. Community Oncol. 2012;9:336.
https://doi.org/10.1016/j.cmonc.2012.10.004
Kimura S. Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia. Stem Cell Investig. 2016;3:36.
https://doi.org/10.21037/sci.2016.07.08
Jabbour E, Deininger M, Hochhaus A. Magnagement od adverse events associated with tyrosine kinase inhubitors in the treatment of chronic myeloid leukemia. Leukemia. 2011;25:201-10.
https://doi.org/10.1038/leu.2010.215
Quintás-Cardama A, Kantarjian H, Ravendi F, O'Brien S, Thomas D, Vidal-Senmache G, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009;115:2482-90.
https://doi.org/10.1002/cncr.24257
Kmira Z, Nesrine BS, Houneida Z, Wafa BF, Aida S, Yosra BY, et al. Severe hemorragic colitis in a patient with chronicmyeloid leukemia in the blastic phase after dasatinib use. World J Gastrointest Pathophysiol. 2013;4:59-62.
https://doi.org/10.4291/wjgp.v4.i3.59
Caldemeyer L, Dugan M, Edwards J, Akard L. Long-Term Side Effects of Tiroside Kinase Inhibitors in Chronic Myeloid Leukemia. Curr Hematol Malig Rep. 2016;11:71-9.
https://doi.org/10.1007/s11899-016-0309-2
Common, Terminology Criteria for Adverse Events (CTCAE) Version 4.0.2009.[Internet] https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE4.032010-06-14QuickReference5x7.pdf.
Baccarani M, Pileri S, Steegmann JL, Muller M, Soverini S, Dreyling M, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii72-7.
https://doi.org/10.1093/annonc/mds228
Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;114:261-3.
https://doi.org/10.1182/blood-2008-09-180604
Neelakantan P, Marin D, Laffan M, Goldman J, Apperley J, Milojkovic D. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy. Haematologica. 2012;97:1444.
https://doi.org/10.3324/haematol.2012.064618
Aguilera DG, Tsimberidou AM. Dasatinib in chronic myeloid leukemia: A review. Ther Clin Risk Manag. 2009;5: 281---9.
https://doi.org/10.2147/TCRM.S3425
Ezumi Y, Shindoh K, Tsuji M, Takayama H. Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets. J Exp Med. 1998;188: 267-76.
https://doi.org/10.1084/jem.188.2.267
Noens L, Hensen M, Kucmin-Bemelmans I, Lofgren C, Gilloteau I, Vrijens B. Measurent of adherence to BCR ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica. 2014;99:437-47.
https://doi.org/10.3324/haematol.2012.082511
Martínez Cordero, H., Análisis de los efectos de las interrupciones en el tratamiento con inhibidores de Tirosina Quinasa en cuanto al logro y mantenimiento de a respuesta molecular en pacientes con Leucemia Mielode Crónica [tesis de grado en, Internet]., [Bogotá]: Universidad Nacional de,Colombia., 2015. [Consultada 02 Jul 2017]. Disponible en: http://www.bdigital.unal.edu.co/50798/1/75100608.2015.pdf.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
